Edward F. Mackey
Net Worth

Last updated:

What is Edward F. Mackey net worth?

The estimated net worth of Mr. Edward F. Mackey is at least $14,299,217 as of 28 Feb 2022. He owns shares worth $2,465,665 as insider, has earned $6,375,112 from insider trading and has received compensation worth at least $5,458,440 in Boston Scientific Corporation.

What is the salary of Edward F. Mackey?

Mr. Edward F. Mackey salary is $909,740 per year as Executive Vice President of Global Operations in Boston Scientific Corporation.

How old is Edward F. Mackey?

Mr. Edward F. Mackey is 62 years old, born in 1963.

What stocks does Edward F. Mackey currently own?

As insider, Mr. Edward F. Mackey owns shares in one company:

Company Title Shares Price per share Total value
Boston Scientific Corporation (BSX) Executive Vice President of Global Operations 23,722 $103.94 $2,465,665

What does Boston Scientific Corporation do?

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX logo
BSX
Boston Scientific Corporation
$103.94

Edward F. Mackey insider trading

Boston Scientific Corporation

Mr. Edward F. Mackey has made 3 insider trades between 2019-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 68,173 units of BSX stock on 1 Jun 2021. As of 28 Feb 2022 he still owns at least 23,722 units of BSX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Deferred Stock Units 2,444 N/A N/A
Option
Common Stock 2,444 N/A N/A
Option
Deferred Stock Units 2,726 N/A N/A
Option
Common Stock 2,726 N/A N/A
Option
Deferred Stock Units 2,223 N/A N/A
Option
Deferred Stock Units 23,719 N/A N/A
Option
Common Stock 2,223 N/A N/A
Option
Restricted Stock Units 2,833 N/A N/A
Option
Common Stock 23,719 N/A N/A
Option
Common Stock 2,833 N/A N/A
Option
Common Stock 2,769 N/A N/A
Option
Deferred Stock Units 2,769 N/A N/A
Option
Performance Share Units 9,824 N/A N/A
Option
Common Stock 9,824 N/A N/A
Sale
Common Stock 68,173 $42.71 $2,911,601
Option
Common Stock 2,444 N/A N/A
Option
Deferred Stock Units 2,444 N/A N/A
Option
Common Stock 2,897 N/A N/A
Option
Deferred Stock Units 2,897 N/A N/A
Option
Common Stock 2,726 N/A N/A
Option
Deferred Stock Units 2,726 N/A N/A
Option
Deferred Stock Units 2,223 N/A N/A
Option
Common Stock 2,223 N/A N/A
Option
Common Stock 2,768 N/A N/A
Option
Deferred Stock Units 2,768 N/A N/A
Option
Common Stock 16,318 N/A N/A
Option
Performance Share Units 16,318 N/A N/A
Option
Deferred Stock Units 19,227 N/A N/A
Option
Common Stock 19,227 N/A N/A
Option
Common Stock 2,444 N/A N/A
Option
Deferred Stock Units 2,444 N/A N/A
Option
Deferred Stock Units 2,300 N/A N/A
Option
Common Stock 2,300 N/A N/A
Option
Deferred Stock Units 2,897 N/A N/A
Option
Common Stock 2,897 N/A N/A
Option
Common Stock 2,726 N/A N/A
Option
Deferred Stock Units 2,726 N/A N/A
Option
Common Stock 2,768 N/A N/A
Option
Deferred Stock Units 2,768 N/A N/A
Option
Common Stock 11,926 N/A N/A
Option
Performance Share Units 11,926 N/A N/A
Sale
Common Stock 55,320 $36.83 $2,037,325
Sale
Common Stock 35,906 $39.72 $1,426,186
Option
Common Stock 19,226 N/A N/A
Option
Deferred Stock Units 19,226 N/A N/A
Option
Common Stock 2,444 N/A N/A
Option
Deferred Stock Units 2,444 N/A N/A